Pharmacological treatment with cabergoline in three cats with acromegaly

Arias, Elber Alberto Soler; García, Jorge D; Castillo, V.

doi:10.17533/udea.rccp.v30n4a07

Cited by 7 publications

(9 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 15 We previously published the first report of cabergoline treatment of hypersomatotropism in cats with successful results. 3 Despite the number of cases and the brief follow-up, serum IGF-1 concentrations and IR decreased significantly in those three cases. 3 Interestingly, in a study from the UK, cabergoline was not effective in controlling DM, lowering IGF-1 and fructosamine, or reducing insulin doses in eight diabetic cats with hypersomatotropism.…”

Section: Discussionmentioning

confidence: 84%

“… 3 Despite the number of cases and the brief follow-up, serum IGF-1 concentrations and IR decreased significantly in those three cases. 3 Interestingly, in a study from the UK, cabergoline was not effective in controlling DM, lowering IGF-1 and fructosamine, or reducing insulin doses in eight diabetic cats with hypersomatotropism. 16 It is currently unclear why some cats do respond to cabergoline and other cats do not.…”

Section: Discussionmentioning

confidence: 84%

“…Hypotheses include the existence of various subpopulations of somatotrophinomas with varied dopamine receptor expression and agonist affinity, regional variants of hypersomatotropism or cat breeds, different dosing regimens and different commercial preparations of cabergoline used in the two studies. 3 , 16 …”

Section: Discussionmentioning

confidence: 99%

“…An oral dose of 10 μg/kg cabergoline (Dostinex; Pfizer) q48h was prescribed. 3 Monitoring of clinical signs, as well as home blood glucose monitoring, was performed by the owners and the veterinary team to try and make appropriate adjustments to the insulin dose (glucose measured with a FreeStyle Optium glucose meter [Abbott]). In the first week of cabergoline treatment, there were no remarkable changes in blood glucose values or clinical signs in any of the cats.…”

Section: Case Descriptionmentioning

confidence: 99%

See 3 more Smart Citations

Diabetes mellitus remission in three cats with hypersomatotropism after cabergoline treatment

Miceli

Vidal

Pompili

et al. 2021

Journal of Feline Medicine and Surgery Open Reports

Self Cite

View full text Add to dashboard Cite

Case summary Three diabetic cats presented with polyuria, polydipsia, polyphagia and poor glycemic control. Cat 1 displayed prognathia inferior and had a body condition score (BCS) of 4/5; cat 2 had a BCS of 5/5; and cat 3 had broad facial features. Serum insulin-like growth factor 1 concentrations were compatible with hypersomatotropism in cat 1 and cat 2 (>1500 ng/ml and 1200 ng/ml, respectively) and just below the cut-off of 1000 ng/ml (947 ng/ml) in cat 3; in this last cat diagnosis was further supported by the presence of pituitary enlargement on MRI. Oral cabergoline (10 μg/kg q48h) was initiated. Insulin requirements progressively reduced, as evidenced by daily blood glucose monitoring and weekly blood glucose curves. Diabetic remission occurred in all three cats between the second and third months of cabergoline treatment. At the time of writing, remission has persisted thus far (cat 1: 23 months; cat 2: 14 months; cat 3: 38 months). Relevance and novel information To our knowledge, these are the first reported cases of diabetic remission in cats with hypersomatotropism after cabergoline treatment, despite previous reports of this being an ineffective treatment. Further work is indicated to determine why some cats do, and others do not, respond to this treatment.

show abstract

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Section: Case Descriptionmentioning

confidence: 99%

See 2 more Smart Citations

Diabetes mellitus remission in three cats with hypersomatotropism after cabergoline treatment

Miceli

Vidal

Pompili

et al. 2021

Journal of Feline Medicine and Surgery Open Reports

Self Cite

View full text Add to dashboard Cite

show abstract

“…2 Studies assessing the use of cabergoline for the treatment of feline HST are lacking, and the results on the effects on blood glucose and the improvement of DM are discordant. 8–10 In a pilot study carried out in the UK, cabergoline did not normalize IGF-1 concentration nor improve diabetic control. 8 Conversely, we reported, for the first time, the remission of DM in three cats with HST treated with cabergoline.…”

Section: Introductionmentioning

confidence: 98%

Cabergoline treatment in cats with diabetes mellitus and hypersomatotropism

Miceli

García

Pompili

et al. 2022

Journal of Feline Medicine and Surgery

Self Cite

View full text Add to dashboard Cite

Objectives The aim of this study was to evaluate the safety and efficacy of cabergoline to control hypersomatotropism (HST) and diabetes mellitus (DM) in cats. Methods This was a prospective cohort study. Twenty-three cats with HST and concurrent DM were enrolled. Cats received a dose of 10 μg/kg cabergoline q48h PO for 6 months. Serum insulin-like growth factor 1 (IGF-1) and fructosamine concentrations, insulin dose and Insulin Resistance Index (IRI) were measured at the time of diagnosis of HST and at the start of cabergoline treatment (t0), and 3 months (t1) and 6 months (t2) during cabergoline treatment. Results A decrease and normalization of serum IGF-1 concentration was observed in 35% and 26% of cats, respectively. Median IGF-1 (t0: 1350 ng/ml [range 832–1501]; t1: 1284 ng/ml [range 365–1501]; t2: 1240 ng/ml [range 263–1501]; P = 0.016) decreased significantly. Twelve cats underwent diagnostic imaging of the pituitary area. The median pituitary height at t0 of cats that experienced an IGF-1 reduction (n = 5/12) was significantly lower compared with those that did not experience an IGF-1 reduction (n = 7/12) (3.2 mm [range 3.1–3.7] vs 6 mm [range 3.5–9.5]; P = 0.011). Median fructosamine (t0: 628 µmol/l [range 400–963]; t1: 404 µmol/l [range 249–780]; t2: 400 µmol/l [range 260–815]; P <0.0001), insulin dose (t0: 1.3 IU/kg [range 0.5–4.6]; t0: 0.5 IU/kg [range 0–2.3]; t2: 0.4 IU/kg [range 0–2.1]; P <0.0001) and IRI (t0: 800 µmolIU/kgl [range 257–2700]; t1: 300 µmolIU/kgl [range 0–1498]; t2: 250 µmolIU/kgl [range 0–1498]; P <0.0001) decreased significantly during cabergoline treatment. Eight cats achieved diabetic remission between months 1 and 6 of cabergoline treatment (median time to achieve remission: 3 months [range 1–6]). Three cats experienced asymptomatic hypoglycemia. Conclusions and relevance Cabergoline was effective in normalizing IGF-1 concentration in 26% of cats. Cabergoline improved diabetes control and was associated with remission of DM in 35% of cases. Cabergoline could be a treatment option for cats with HST and DM, especially in those cases with a relatively small pituitary tumor.

show abstract